| Literature DB >> 31454332 |
Nathalie Tisch1,2,3, Aida Freire-Valls1,4, Rosario Yerbes1,5, Isidora Paredes1,2,3, Silvia La Porta2,6, Xiaohong Wang1, Rosa Martín-Pérez7,8, Laura Castro1, Wendy Wei-Lynn Wong9, Leigh Coultas10,11, Boris Strilic12, Hermann-Josef Gröne13, Thomas Hielscher14, Carolin Mogler15, Ralf H Adams16,17, Peter Heiduschka18, Lena Claesson-Welsh19, Massimiliano Mazzone7,8, Abelardo López-Rivas5,20, Thomas Schmidt4, Hellmut G Augustin2,6, Carmen Ruiz de Almodovar1,2,3.
Abstract
During developmental angiogenesis, blood vessels grow and remodel to ultimately build a hierarchical vascular network. Whether, how, cell death signaling molecules contribute to blood vessel formation is still not well understood. Caspase-8 (Casp-8), a key protease in the extrinsic cell death-signaling pathway, regulates cell death via both apoptosis and necroptosis. Here, we show that expression of Casp-8 in endothelial cells (ECs) is required for proper postnatal retina angiogenesis. EC-specific Casp-8-KO pups (Casp-8ECKO) showed reduced retina angiogenesis, as the loss of Casp-8 reduced EC proliferation, sprouting, and migration independently of its cell death function. Instead, the loss of Casp-8 caused hyperactivation of p38 MAPK downstream of receptor-interacting serine/threonine protein kinase 3 (RIPK3) and destabilization of vascular endothelial cadherin (VE-cadherin) at EC junctions. In a mouse model of oxygen-induced retinopathy (OIR) resembling retinopathy of prematurity (ROP), loss of Casp-8 in ECs was beneficial, as pathological neovascularization was reduced in Casp-8ECKO pups. Taking these data together, we show that Casp-8 acts in a cell death-independent manner in ECs to regulate the formation of the retina vasculature and that Casp-8 in ECs is mechanistically involved in the pathophysiology of ROP.Entities:
Keywords: Angiogenesis; Apoptosis pathways; Caspases and caspase substrates; Retinopathy
Mesh:
Substances:
Year: 2019 PMID: 31454332 PMCID: PMC6877326 DOI: 10.1172/JCI122767
Source DB: PubMed Journal: J Clin Invest ISSN: 0021-9738 Impact factor: 14.808